241 related articles for article (PubMed ID: 22595378)
41. Performance of cervicovaginal fetal fibronectin in a community hospital setting.
Incerti M; Ghidini A; Korker V; Pezzullo JC
Arch Gynecol Obstet; 2007 May; 275(5):347-51. PubMed ID: 17051404
[TBL] [Abstract][Full Text] [Related]
42. Relationship between interpregnancy interval and cervical length in high-risk women.
Subramaniam A; Wetta LL; Owen J
J Matern Fetal Neonatal Med; 2016; 29(8):1205-8. PubMed ID: 25983138
[TBL] [Abstract][Full Text] [Related]
43. Contingent use of fetal fibronectin testing and cervical length measurement in women with preterm labour.
Audibert F; Fortin S; Delvin E; Djemli A; Brunet S; Dubé J; Fraser WD
J Obstet Gynaecol Can; 2010 Apr; 32(4):307-12. PubMed ID: 20500936
[TBL] [Abstract][Full Text] [Related]
44. The use of progestational agents for preterm birth: lessons from a mouse model.
Elovitz MA; Mrinalini C
Am J Obstet Gynecol; 2006 Oct; 195(4):1004-10. PubMed ID: 17000233
[TBL] [Abstract][Full Text] [Related]
45. Accuracy of fetal fibronectin to predict preterm birth in twin gestations with symptoms of labor.
Singer E; Pilpel S; Bsat F; Plevyak M; Healy A; Markenson G
Obstet Gynecol; 2007 May; 109(5):1083-7. PubMed ID: 17470586
[TBL] [Abstract][Full Text] [Related]
46. Pregnancy outcomes of managed Medicaid members prescribed home administration of 17 α-hydroxyprogesterone caproate.
Lucas B; Poole-Yaeger A; Istwan N; Stanziano G; Rhea D; Mason M
Am J Perinatol; 2012 Aug; 29(7):489-96. PubMed ID: 22399213
[TBL] [Abstract][Full Text] [Related]
47. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?
How HY; Barton JR; Istwan NB; Rhea DJ; Stanziano GJ
Am J Obstet Gynecol; 2007 Sep; 197(3):260.e1-4. PubMed ID: 17826411
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of the effectiveness of foetal fibronectin as a predictor of preterm birth in symptomatic preterm labour women.
Jun SY; Lee JY; Kim HM; Kim MJ; Cha HH; Seong WJ
BMC Pregnancy Childbirth; 2019 Jul; 19(1):241. PubMed ID: 31296172
[TBL] [Abstract][Full Text] [Related]
49. "Blind" vaginal fetal fibronectin as a predictor of spontaneous preterm delivery.
Roman AS; Koklanaris N; Paidas MJ; Mulholland J; Levitz M; Rebarber A
Obstet Gynecol; 2005 Feb; 105(2):285-9. PubMed ID: 15684153
[TBL] [Abstract][Full Text] [Related]
50. Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting.
Rittenberg C; Sullivan S; Istwan N; Rhea D; Stanziano G; Newman R
Am J Obstet Gynecol; 2007 Sep; 197(3):262.e1-4. PubMed ID: 17826412
[TBL] [Abstract][Full Text] [Related]
51. Utility of cervical length and quantitative fetal fibronectin for predicting spontaneous preterm delivery among symptomatic nulliparous women.
Kyozuka H; Murata T; Sato T; Suzuki S; Yamaguchi A; Fujimori K
Int J Gynaecol Obstet; 2019 Jun; 145(3):331-336. PubMed ID: 30941761
[TBL] [Abstract][Full Text] [Related]
52. The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage.
Rebarber A; Cleary-Goldman J; Istwan NB; Rhea DJ; Desch C; Russo-Stieglitz K; Saltzman DH
Am J Perinatol; 2008 May; 25(5):271-5. PubMed ID: 18401840
[TBL] [Abstract][Full Text] [Related]
53. Prediction of spontaneous preterm delivery in women with threatened preterm labour: a prospective cohort study of multiple proteins in maternal serum.
Tsiartas P; Holst RM; Wennerholm UB; Hagberg H; Hougaard DM; Skogstrand K; Pearce BD; Thorsen P; Kacerovsky M; Jacobsson B
BJOG; 2012 Jun; 119(7):866-73. PubMed ID: 22530716
[TBL] [Abstract][Full Text] [Related]
54. Spontaneous preterm birth in African-American and Caucasian women receiving 17α-hydroxyprogesterone caproate.
Timofeev J; Singh J; Istwan N; Rhea D; Driggers RW
Am J Perinatol; 2014 Jan; 31(1):55-60. PubMed ID: 23456908
[TBL] [Abstract][Full Text] [Related]
55. Placental inflammation and its relationship to cervicovaginal fetal fibronectin in preterm birth.
van der Krogt L; Ridout AE; Seed PT; Shennan AH
Eur J Obstet Gynecol Reprod Biol; 2017 Jul; 214():173-177. PubMed ID: 28535404
[TBL] [Abstract][Full Text] [Related]
56. The value of combined cervical length measurement and fetal fibronectin testing to predict spontaneous preterm birth in asymptomatic high-risk women.
Bolt LA; Chandiramani M; De Greeff A; Seed PT; Kurtzman J; Shennan AH
J Matern Fetal Neonatal Med; 2011 Jul; 24(7):928-32. PubMed ID: 21190414
[TBL] [Abstract][Full Text] [Related]
57. Will cervicovaginal interleukin-6 combined with fetal fibronectin testing improve the prediction of preterm delivery?
LaShay N; Gilson G; Joffe G; Qualls C; Curet L
J Matern Fetal Med; 2000; 9(6):336-41. PubMed ID: 11243290
[TBL] [Abstract][Full Text] [Related]
58. Prediction of spontaneous preterm birth in asymptomatic twin pregnancies with the use of combined fetal fibronectin and cervical length.
Fox NS; Saltzman DH; Klauser CK; Peress D; Gutierrez CV; Rebarber A
Am J Obstet Gynecol; 2009 Sep; 201(3):313.e1-5. PubMed ID: 19733285
[TBL] [Abstract][Full Text] [Related]
59. Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial.
Senat MV; Porcher R; Winer N; Vayssière C; Deruelle P; Capelle M; Bretelle F; Perrotin F; Laurent Y; Connan L; Langer B; Mantel A; Azimi S; Rozenberg P;
Am J Obstet Gynecol; 2013 Mar; 208(3):194.e1-8. PubMed ID: 23433324
[TBL] [Abstract][Full Text] [Related]
60. Risk stratification with cervical length and fetal fibronectin in women with threatened preterm labor before 34 weeks and not delivering within 7 days.
Hermans FJR; Bruijn MMC; Vis JY; Wilms FF; Oudijk MA; Porath MM; Scheepers HCJ; Bloemenkamp KWM; Bax CJ; Cornette JMJ; Nij Bijvanck BWA; Franssen MTM; Vandenbussche FPHA; Kok M; Grobman WA; Van Der Post JAM; Bossuyt PMM; Opmeer BC; Mol BWJ; Schuit E; Van Baaren GJ
Acta Obstet Gynecol Scand; 2015 Jul; 94(7):715-721. PubMed ID: 25845495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
